Back to Press Releases

Revance Launches the Teoxane RHA® Collection with Mepivacaine

The innovative filler line challenges the status quo by replacing the local anesthetic with mepivacaine.

Revance Launches the Teoxane RHA® Collection with Mepivacaine

Nashville, TN – August 27, 2025 – Revance, a fast-growing global aesthetics and skincare company, announces the latest innovation in its aesthetic portfolio with the launch of the Teoxane RHA® Collection with Mepivacaine.1 As of today, mepivacaine will replace lidocaine as the anesthetic in the Teoxane RHA® Collection in the U.S. market, celebrating the first major anesthetic innovation in hyaluronic acid filler in almost two decades. 2

The Teoxane RHA® Collection with Mepivacaine received FDA approval in 2023 and is exclusively patented by Teoxane for use in dermal fillers. 1,3-7 This deliberate, research-driven innovation delivers patient comfort with patient care in mind. 8-9 While new to the aesthetic market, mepivacaine has been widely used in therapeutic areas for over 60 years. 10 Mepivacaine features the same mechanism of action as lidocaine, with less local vasodilation, reducing the potential for injection site reactions such as bruising. 9-11 Preclinical and clinical studies comparing RHA Redensity® with Mepivacaine to RHA Redensity® with lidocaine, as well as RHA® 4 with Mepivacaine to RHA® 4 with lidocaine found similar rheology, effective pain control, established safety profile, and no change in aesthetic outcomes. 1,8,12

“The development of the Teoxane RHA® Collection with Mepivacaine exemplifies Teoxane’s commitment to innovation,” states Valérie Taupin, Founder and CEO of Teoxane. “Mepivacaine represents the first major advancement in pain management in fillers in nearly two decades. It provides an anesthetic effect comparable to currently available products, but with reduced local vasodilation, as demonstrated in the recent article published in RSC Pharmaceutics, 2025, which may result in less bruising. We are proud to bring this patented innovation to providers and offer great patient comfort. Teoxane is leading the way in a next-generation approach to optimal patient experience in aesthetics.

“It’s incredibly rewarding to help bring the next evolution of RHA® to the U.S. market. The addition of mepivacaine reflects our commitment to advancing the patient experience without compromising the outcomes providers have come to expect from the RHA® Collection by Teoxane. We’re proud to lead the way in innovation that matters to both patients and practices,” states Jeff Bedard, Founder and CEO, Revance.

Learn more at rha.revanceaesthetics.com.

About Revance:
Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets.

Revance’s balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, the Teoxane RHA® Collection, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the Teoxane RHA® Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®.

RHA® is a trademark of TEOXANE SA.

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

About Teoxane:
Founded by Valérie Taupin in 2003, Teoxane specializes in developing solutions using hyaluronic acid. With over 20 years of expertise, it is a pioneer in the science of facial beauty. The company was founded on a unique vision: to open the possibilities of aesthetic treatments using high-performance dermal and dermo-cosmetic fillers developed through in-depth scientific research. Through attentive listening, education and establishing the foundations for a safer industry, Teoxane has ushered in a new era in aesthetic medicine. Here, minor beauty procedures wield a significant impact on a patient’s self-image and overall well-being.

www.teoxane.com

Media Contact:
EvolveMKD
Revance@EvolveMKD.com

References:

  1. RHA® Directions for Use. 2025.
  2. Micheels P, Besse S, Elias B, et al. J Clin Cosmet Dermatol 8(1): dx.doi.org/70.16966/2576-2826.180
  3. US11,406,738
  4. US10,413,637
  5. US10,786,601
  6. US10,322,212
  7. US97,892,26
  8. Kaufman-Janette J, Joseph JH, Dayan SH, et al. Dermatol surg. 2022;48(10):1065- 1070.
  9. Faivre J, Brusini R, Jing J et al. RSC Pharmaceutics. 2025,2,814-823
  10. Brockmann WG. Gen Dent. 2014;62(6):70-75.
  11. Catterall WA, Mackie K. Local anesthetics. In: McGraw-Hill, ed. The Pharmacological Basis of Therapeutics. Vol 12th ed. New York, NY: Goodman & Gilman’s 2011:565-582.
  12. Brusini R, Iehl J, Clerc E, et al. Pharmaceutics. 2022.26:14(8):1553

RHA® Collection of Fillers, by Teoxane

The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine and have shown no significant impact on gel properties, including rheology and degradation profile.

Approved Uses
The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4.

RHA Redensity® is for injection into the facial tissue for the correction of moderate to severe dynamic perioral rhytids; and RHA® 2 and RHA® 4 are for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults 22 or older. RHA® 3 is for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, and also used to augment lip fullness in adults 22 or older.

IMPORTANT SAFETY INFORMATION

Are there any reasons why I should not receive any RHA® injectable gel formulation?
Do not receive if you have a history of multiple severe allergies or severe allergic reactions; if you are allergic to lidocaine or mepivacaine or gram-positive bacterial proteins; or if you have a bleeding disorder.

What precautions should I discuss with my doctor?

  • Tell your doctor if you are pregnant or breastfeeding as the safety of these products for use during pregnancy or while breastfeeding has not been studied
  • Tell your doctor if you have a history of excessive scarring, keloid formations or pigmentation disorders, as use of these products may result in additional scars or changes in pigmentation
  • Tell your doctor if you are planning laser treatments or a chemical peel, as there is a possible risk of inflammation at the treatment site if these procedures are performed after treatment
  • Tell your doctor if you are on immunosuppressive therapy used to decrease your immune response, as use of these products may result in an increased risk of infection
  • Tell your doctor if you are using medications that can prolong bleeding, such as aspirin, ibuprofen, or other blood thinners, as this may increase bruising or bleeding at the injection site
  • The safety and effectiveness of RHA® fillers in areas other than those indicated have not been established in U.S. clinical studies
  • Patients who experience skin injury near the site of injection with this product may be at a higher risk for side effects
  • Minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment

What are possible side effects?
The most commonly reported side effects included injection-site redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching.

One of the risks with using these products is unintentional injection into a blood vessel, and while rare, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring.

Delayed-onset inflammation near the site of dermal filler injections is one of the known side effects associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures.

Typically, the reported inflammation was responsive to being treated or resolved on its own.

As with all skin injection procedures, there is a risk of infection and recurrence of herpetic eruptions.

To report a side effect with any RHA® product, please call Revance at (877) 373-8669. Please visit RHACollection.com or talk to your doctor for more information.

©2025 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.

Available by prescription only.

RHA-00220

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.